Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 52

1.

Sodium intake and multiple sclerosis activity and progression in BENEFIT.

Fitzgerald KC, Munger KL, Hartung HP, Freedman MS, Montalbán X, Edan G, Wicklein EM, Radue EW, Kappos L, Pohl C, Ascherio A; BENEFIT Study Group.

Ann Neurol. 2017 Jul;82(1):20-29. doi: 10.1002/ana.24965.

PMID:
28556498
2.

The 11-year long-term follow-up study from the randomized BENEFIT CIS trial.

Kappos L, Edan G, Freedman MS, Montalbán X, Hartung HP, Hemmer B, Fox EJ, Barkhof F, Schippling S, Schulze A, Pleimes D, Pohl C, Sandbrink R, Suarez G, Wicklein EM; BENEFIT Study Group.

Neurology. 2016 Sep 6;87(10):978-87. doi: 10.1212/WNL.0000000000003078. Epub 2016 Aug 10.

3.

Interferon β-1b-neutralizing antibodies 5 years after clinically isolated syndrome.

Hartung HP, Freedman MS, Polman CH, Edan G, Kappos L, Miller DH, Montalbán X, Barkhof F, Petkau J, White R, Sahajpal V, Knappertz V, Beckmann K, Lanius V, Sandbrink R, Pohl C; BENEFIT Study Group.

Neurology. 2011 Aug 30;77(9):835-43. doi: 10.1212/WNL.0b013e31822c90d7. Epub 2011 Aug 17. Erratum in: Neurology. 2011 Sep 27;77(13):1317.

PMID:
21849647
4.

Prevention of episodic migraine with topiramate: a prospective 24-week, open-label, flexible-dose clinical trial with optional 24 weeks follow-up in a community setting.

Malessa R, Gendolla A, Steinberg B, Schmitt L, Bornhoevd K, Djelani M, Schäuble B; TOPMAT-MIG-3004 investigators.

Curr Med Res Opin. 2010 May;26(5):1119-29. doi: 10.1185/03007991003676461.

PMID:
20225996
5.

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial.

Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, Montalbán X, Barkhof F, Radü EW, Metzig C, Bauer L, Lanius V, Sandbrink R, Pohl C; BENEFIT Study Group.

Lancet Neurol. 2009 Nov;8(11):987-97. doi: 10.1016/S1474-4422(09)70237-6. Epub 2009 Sep 10.

PMID:
19748319
6.

250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.

O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D, Hartung HP, Jeffery D, Kappos L, Boateng F, Filippov V, Groth M, Knappertz V, Kraus C, Sandbrink R, Pohl C, Bogumil T; BEYOND Study Group, O'Connor P, Filippi M, Arnason B, Cook S, Goodin D, Hartung HP, Kappos L, Jeffery D, Comi G.

Lancet Neurol. 2009 Oct;8(10):889-97. doi: 10.1016/S1474-4422(09)70226-1. Epub 2009 Sep 2. Erratum in: Lancet Neurol. 2011 Feb;10(2):115. Lancet Neurol. 2009 Nov;8(11):981. Lancet Neurol. 2012 Jan;11(1):27. Cree, B [added]; Harung, H-P [corrected to Hartung, H-P].

PMID:
19729344
7.

Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations.

Multiple Sclerosis Therapy Consensus Group (MSTCG), Wiendl H, Toyka KV, Rieckmann P, Gold R, Hartung HP, Hohlfeld R.

J Neurol. 2008 Oct;255(10):1449-63. doi: 10.1007/s00415-008-0061-1. Epub 2008 Oct 29.

PMID:
19005625
8.

Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b.

Polman C, Kappos L, Freedman MS, Edan G, Hartung HP, Miller DH, Montalbán X, Barkhof F, Selmaj K, Uitdehaag BM, Dahms S, Bauer L, Pohl C, Sandbrink R; BENEFIT investigators.

J Neurol. 2008 Apr;255(4):480-7. Epub 2007 Nov 15.

PMID:
18004635
9.

Escalating immunotherapy of multiple sclerosis--new aspects and practical application.

Rieckmann P, Toyka KV, Bassetti C, Beer K, Beer S, Buettner U, Chofflon M, Götschi-Fuchs M, Hess K, Kappos L, Kesselring J, Goebels N, Ludin HP, Mattle H, Schluep M, Vaney C, Baumhackl U, Berger T, Deisenhammer F, Fazekas F, Freimüller M, Kollegger H, Kristoferitsch W, Lassmann H, Markut H, Strasser-Fuchs S, Vass K, Altenkirch H, Bamborschke S, Baum K, Benecke R, Brück W, Dommasch D, Elias WG, Gass A, Gehlen W, Haas J, Haferkamp G, Hanefeld F, Hartung HP, Heesen C, Heidenreich F, Heitmann R, Hemmer B, Hense T, Hohlfeld R, Janzen RW, Japp G, Jung S, Jügelt E, Koehler J, Kölmel W, König N, Lowitzsch K, Manegold U, Melms A, Mertin J, Oschmann P, Petereit HF, Pette M, Pöhlau D, Pohl D, Poser S, Sailer M, Schmidt S, Schock G, Schulz M, Schwarz S, Seidel D, Sommer N, Stangel M, Stark E, Steinbrecher A, Tumani H, Voltz R, Weber F, Weinrich W, Weissert R, Wiendl H, Wiethölter H, Wildemann U, Zettl UK, Zipp F, Zschenderlein R, Izquierdo G, Kirjazovas A, Packauskas L, Miller D, Koncan Vracko B, Millers A, Orologas A, Panellus M, Sindic CJ, Bratic M, Svraka A, Vella NR, Stelmasiak Z, Selmaj K, Bartosik-Psujik H, Mitosek-Szewczyk K, Belniak E, Mochecka A, Bayas A, Chan A, Flachenecker P, Gold R, Kallmann B, Leussink V, Mäurer M, Ruprecht K, Stoll G, Weilbach FX; Multiple Sclerosis Therapy Consensus Group.

J Neurol. 2004 Nov;251(11):1329-39. Review.

PMID:
15592728
10.
11.

Raised intracranial pressure in chronic respiratory disease.

Brockmeier B, Burbach H, Runge M, Altenkirch H.

Lancet. 1997 Mar 22;349(9055):883. No abstract available.

PMID:
9121290
12.

Neurological investigations in 23 cases of pyrethroid intoxication reported to the German Federal Health Office.

Altenkirch H, Hopmann D, Brockmeier B, Walter G.

Neurotoxicology. 1996 Fall-Winter;17(3-4):645-51.

PMID:
9086485
13.

Clinical data on three cases of occupationally induced PCB-intoxication.

Altenkirch H, Stoltenburg G, Haller D, Hopmann D, Walter G.

Neurotoxicology. 1996 Fall-Winter;17(3-4):639-43.

PMID:
9086484
14.

[Multiple chemical sensitivity syndrome].

Altenkirch H.

Gesundheitswesen. 1995 Oct;57(10):661-6. German.

PMID:
8527883
15.

PCBs have a predominantly neurotoxic effect on dissociated cultures of the nervous system.

Boegner F, Franke D, Altenkirch H, Stoltenburg G, Wagner M.

Neurotoxicology. 1994 Fall;15(3):593-6.

PMID:
7854592
16.

Specific neurotoxic effects of different organic solvents on dissociated cultures of the nervous system.

Stoltenburg-Didinger G, Boegner F, Grüning W, Wagner M, Marx P, Altenkirch H.

Neurotoxicology. 1992 Spring;13(1):161-4.

PMID:
1508416
17.

2,5-Hexanedione is a potent gliatoxin in in-vitro cell cultures of the nervous system.

Boegner F, Grüning W, Stoltenburg-Didinger G, Marx P, Altenkirch H.

Neurotoxicology. 1992 Spring;13(1):151-4.

PMID:
1508415
18.

[Sniffing disorder. Abuse of housekeeping and industrial chemicals].

Altenkirch H.

Dtsch Krankenpflegez. 1991 Apr;44(4):283-6. German. No abstract available.

PMID:
2044457
19.

Type 2a fibre rhabdomyolysis in myoadenylate deaminase deficiency.

Zimmer C, Altenkirch H, Dorfmüller-Küchlin S, Pongratz D, Paetzke I, Gosztonyi G.

J Neurol. 1991 Feb;238(1):31-3.

PMID:
2030369
20.

Effects of lipoic acid in hexacarbon-induced neuropathy.

Altenkirch H, Stoltenburg-Didinger G, Wagner HM, Herrmann J, Walter G.

Neurotoxicol Teratol. 1990 Nov-Dec;12(6):619-22.

PMID:
2255304

Supplemental Content

Loading ...
Support Center